Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma

Journal of Clinical Pathology

Volumn 66, Issue 9, 2013, Pages 779-786

  Downes, Michelle R ^a   Torlakovic, Emina E ^a   Aldaoud, Najla ^a,b   Zlotta, Alexandre R ^a   Evans, Andrew J ^a   Van Der Kwast, Theodorus H ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN 20; CYTOKERATIN 7; PROTEIN P63;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; CANCER DIAGNOSIS; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; INSTITUTIONAL REVIEW; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

BLADDER; IMMUNOHISTOCHEMISTRY; PROSTATE;

AGED; AGED, 80 AND OVER; CARCINOMA; CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84882827106     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201586     Document Type: Article

References (34)

1. Lubahn DB, Joseph DR, Sar M, et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988;2:1265-75.
2. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-62.
3. Ruizeveld de Winter JA, Trapman J, Vermey M, et al. Androgen receptor expression in human tissues: An immunohistochemical study. J Histochem Cytochem 1991;39:927-36.
4. Kimura N, Mizokami A, O Onuma T, et al. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin embedded human tissues. J Histochem Cytochem 1993;41:671-78.
5. Chang C, Chodak G, Sarac E, et al. Prostate androgen receptor: immunohistological localization and mRNA characterization. J Steroid Biochem 1989;34:311-13.
6. Masai M, Sumiya H, Akimoto S, et al. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 1990;17:293-00.
7. Takeda H, Chodak G, Mutchnik S, et al. Immunohistochemical localization of androgen receptors with mono-and polyclonal antibodies to androgen receptor. J Endocrinol 1990;126:17-25.
8. Janssen PJ, Brinkmann AO, Boersma WJ, et al. Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processes paraffin embedded human tissues after microwave pre-treatment. J Histochem Cytochem 1994;42:1169-75.
9. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2010. Toronto, Canada, 2010.
10. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging, grading and diagnosis. Urology 2005;66:(Suppl 1):S4-34.
11. Mir C, Shariat SF, van der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: A large multi-institutional study. BJU Int 2010;108:24-30.
12. Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 2011;29:43-51.
13. Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 2012;109:1716-26.
14. Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumour stage in bladder cancer. Urology 2004;64:383-88.
15. Birtle AJ, Freeman A, Munson P. The androgen receptor revisited in urothelial carcinoma. Histopathology 2004;45:87-99.
16. Zhuang YH, Blauer M, Tammela T, et al. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 1997;30:556-62.
17. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
18. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18.
19. Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on prostate cancer part 1: screening, diagnosis and treatment of clinically localized disease. Eur Urol 2011;59:61-71.
20. Mottet N, Bellmunt J, Bolla M, et al. EAU Guidelines on prostate cancer part 2: Treatment of advanced, relapsing and castration resistant prostate cancer. Eur Urol 2011;59:572-83.
21. Petraki CD, Sfikas CP. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 2007;1:107-18.
22. Tetu B. Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma. Best Prac Res Clin Endo Metab 2008;22:271-83.
23. Evans AJ, Ryan P, van der Kwast T. Treatment effects in the prostate including those associated with traditional and emerging therapies. Adv Anat Pathol 2011;18:281-93.
24. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 2005;47:1-16.
25. Aihara M, Lebovitz RM, Wheeler TM, et al. Prostate specific antigen and Gleason grade: An immunohistochemical study of prostate cancer. J Urol 1994;151:1558-64.
26. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002;117:471-77.
27. Varma M, Morgan M, Jasani B, et al. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA. Implications for diagnostic prostatic pathology. Am J Clin Pathol 2002;118:202-07.
28. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin and cytokeratin 20 in noninvasive, invasive and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003;27:1-10.
29. Cheville JC. Urothelial carcinoma of the prostate. An immunohistochemical comparison with high grade prostatic adenocarcinoma and review of the literature. J Urol Pathol 1998;9:141-54.
30. Bassily NH, Vallorosi CJ, Akdas G, et al. Coordinate expression of CK7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol 2000;113:383-88.
31. Varma M, Morgan M, Amin MB, et al. High molecular weight cytokeratin antibody (clone 34betaE12): A sensitive marker for differentiation of high grade invasive urothelial carcinoma from prostate cancer. Histopathology 2003;42:167-72.
32. Chuang AY. DeMarzo AM, Veltri RW et al. Immunohistochemical differentiation of high grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007;31:1246-55.
33. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol 1998;110:385-90.
34. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 2008;16:513-20.